Neurodegenerative disease. CSF biomarkers differentiate between two forms of frontotemporal lobar degeneration.

摘要

Novel cerebrospinal fluid (CSF) biomarkers can potentially identify patients with one or other of the two main forms of frontotemporal lobar degeneration (FTLD), according to research conducted by John Trojanowski and colleagues at the University of Pennsylvania School of Medicine, USA. Identification of the underlying pathology of FTLD in living patients could "enable early and reliable diagnosis of this disorder, so that therapies, when available, can be given early in the disease process when they are most likely to have the greatest efficacy?' says Trojanowski.